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A B S T R A C T
Bone remodeling is a process that occurs continuously in a seemingly inactive tissue like bone. Because of decreased
vitamin D synthesis, phosphorus retention and decreased calcium blood concentration, patients with chronic renal fail-
ure (CRF) develop secondary hyperparathyroidism1–5. Elevated PTH levels shifts balance between osteoblast and osteo-
clast activity in favor of osteoclast activity and, therefore, bone resorption. Bone metabolic disorder that affects patients
with CRF is called renal osteodystrophy (ROD)1–5. We presume that renal transplantation reverses bone metabolism dis-
order and our goal was to establish whether osteoblast and osteoclast activity returns to the levels of healthy individuals.
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Introduction
Bone is a very dynamic organ that gives our organism
maximal strength with minimal mass1. There is constant
activity in bone that is called bone remodeling. Osteo-
blasts continuously form new bone and osteoclasts re-
sorb the old one. In healthy individuals there is balance
between osteoblast and osteoclast activity. Among other
diseases, chronic renal failure also affects bone metabo-
lism and remodeling. Because of phosphate retention, de-
creased blood calcium and vitamin D levels, patients with
CRF develop secondary hyperparathyroidism. It is known
that parathyroid hormone (PTH) is major regulator of
bone turnover2,3. An excess of PTH shifts balance be-
tween osteoblast and osteoclast activity in favor to osteo-
clast activity and therefore bone resorption4. Distur-
bances in bone metabolism in CRF patients are called
renal osteodystrophy (ROD).
To evaluate osteoblast and osteoclast activity we have
measured bone specific alkaline phosphatase (BAP) and
tartrate-resistant acid phosphatase isoform 5b (TRAP
5b). BAP is exclusively produced by osteoblast and is de-
graded in the liver5. TRAP 5b is produced by osteoclasts
during bone resorption. It correlates with osteoclast ac-
tivity and does not cumulate in renal insufficiency6,7.
We presume that renal transplantation reverses bone
metabolism disorder. The aim of this study was to see
whether the levels of bone markers that represent the ac-




To avoid circadian variations, venous blood was drawn
in the morning after overnight fast. Blood samples were
collected three times in transplantation group (at the day
of transplantation, 6 and 12 months after – Tx0, Tx6 and
Tx12 group) and once in control group. The samples
were centrifuged and sera aliquoted and stored at –80°C.
No repeated thawing and freezing cycles occurred.
Transplantation group
The study population was consisted of 17 kidney
allograft recipients (age range 25–67 years, 15 male and
2 female) who were enrolled at the moment of transplan-
tation and followed up 6 and 12 months post transplant.
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All patients were with stable graft function (serum crea-
tinine 1.5±0.3 mg/dL), free of infections, liver dysfunc-
tion and 3 of them had undergone subtotal parathy-
reoidectomy. The immunosuppressive therapy included
prednisone, mycophenolate mofetil and tacrolimus. Time
on dialysis prior to transplantation in average was 94±96,6
months. The study was approved by institutional ethics
committee and written informed consent was obtained
from all participants.
Control group
A control group of 23 healthy individuals matched for
sex and age was studied at the same time. Inclusion crite-
ria for this group were no bone and renal diseases, no
therapy with medications that affect normal bone forma-
tion and normal PTH levels.
Biochemical markers
Intact PTH (iPTH) was measured using IMMULITE/
IMMULITE 1000 Intact PTH (Siemens Medical Solution
Diagnostics, Deerfield, USA). Assay is highly specific for
intact PTH, with low crossreactivity to most PTH frag-
ments. The CV's of intra- and interassay were < 8%, and
the sensitivity is 3 pg/mL (0.3 pmol/L).
Bone specific alkaline phosphatase (BAP) was mea-
sured with immunoassay from MetraBAP (Metra Bio-
systems, Mountain View, CA, USA). The intra- and inter
assay CV is also <8%. The minimum detection limit of
the assay is 0.7 U/L.
Tartrate-resistant acid phosphatase isoform 5b (TRAP5b)
was estimated using immunocapture enzyme assay Me-
traTRAP5b (Metra Biosystems, Mountain View, CA, USA),
whose detection limit was 0.2U/L and intra-interassay
CV's were <3%.
Statistical analysis
Statistical analysis was performed using Statistica 8
software (StatSoft, Inc., Tulsa, OK, USA). All results
were expressed as median and range, or mean±SD. Dif-
ferences between the groups were analyzed using Stu-
dent t-test and one-way ANOVA, following Duncan's post
hoc test. A probability level of 0.05 was chosen for statis-
tical significance.
Results
In healthy controls concentrations of iPTH were
within assay normal range (1.6–6.9 pmol/L), whereas in
Tx0 group iPTH values exceeded significantly normal
range with the median of 86 pmol/L (p<0.001). Other
two transplantation groups showed lower iPTH values
compared to Tx0 group with median 12.4 pmol/L in Tx6
group, and 10.4 pmol/L in Tx12 group (level of signifi-
cance for Tx6 and Tx12 group versus Tx0 was p<0.001).
Compared to controls Tx6 and Tx12 group had elevated
levels of iPTH, although this increasement was mild
(p<0.33; 0.31, respectively; Figure 1).
BAP values in control group were below estimated
median for the assay used, and in our hands median
value measured is 12.3 U/L. In Tx0 group BAP had simi-
lar values as in control group with median 12.05 U/L.
Post transplantation groups showed increased BAP val-
ues compared both to control and Tx0 group. In Tx6
group BAP median was 32.97 U/L, and in Tx12 group
29.83 U/L. Observed differences were statistically signifi-
cant (Tx6 versus control p<0.02; Tx12 versus control
p<0.001; Tx12 versus Tx0 p<0.001; Figure 2).
Median concentration of TRAP5b in controls was 2.0
U/L. Unlike controls, Tx0 group had increased values of
TRAP5b with median 3.7 U/L, but no statistical signifi-
cance was observed (Figure 3). In Tx6 group TRAP5b
values resembled to those in control group with median
2.2 U/L. The highest value of TRAP 5b was noticed in
Tx12 group with median 4.1U/L. Differences of TRAP5b
concentrations between control and Tx12 group were
statistically significant (p<0.001).
Discussion and Conclusion
This study evaluated 17 kidney transplant recipients
to determine alterations of bone markers during one
year after transplantation, and their correlation with
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Fig. 1. PTH median and minimal-maximal range in examined
groups; control group, Tx0 = at the time of transplantation, Tx6
= six months after transplantation, Tx12 = twelve months after
transplantation, * statistically significant versus control, Tx6
and Tx12.
Fig. 2. BAP median and minimal-maximal range in examined
groups; control group, Tx0 = at the time of transplantation, Tx6
= six months after transplantation, Tx12 = twelve months after
transplantation, * statistically significant versus control; # sta-
tistically significant versus Tx0.
healthy control serum values. For the first time partici-
pants entered the study at the day of transplantation,
and were followed twice during first year. We had the
rare opportunity to observe dynamic changes of serum
values regarding bone metabolism in homogenized and
time controlled survey.
Parathyroid hormone (PTH) levels increase with de-
terioration of kidney function8. PTH levels decrease and
stabilize one year after renal transplantation9. It is well
known that elevated PTH affects bone metabolism by
stimulating osteoblasts and osteoclasts activity either di-
rectly or by modulating cytokines secretion. Such overac-
tivity leads to formation of low quality bone and disorder
known as renal osteodistrophy4,6.
It was previously investigated that PTH levels de-
crease during six months to few years after transplan-
tation10,11. In consistence with these findings we showed
that one year following the transplantation PTH values
almost reach those in control group. The substantial de-
cline of PTH levels is observed after six months and im-
provement of hyperparathyroidism continues to first year
post transplantation. Because PTH normalizes we hy-
pothesized that osteoblast and osteoclast overactivity
present in CRF also normalize. To prove that thesis we
analyzed BAP and TRAP5b as markers of osteoblasts
and osteoclasts.
Probably the most studied bone marker besides PTH
is BAP. Throughout first year of post transplant period
BAP values are persistently higher compared to control
group. Also, in our study is seen that BAP unlike PTH in-
creases during time after transplantation. In other stud-
ies BAP levels were also higher in the first post trans-
plantation year, in later period decreasing trend began12.
Previously Reinhardt et al. reported increasement of
BAP and osteocalcin in first few months after transplan-
tation and gradual normalization after first year13.
The least explored bone marker in kidney transplant
recipients is surely, TRAP5b. In previous studies statisti-
cally significant correlation was found between TRAP5b
and PTH, also it was found negative correlation of TRAP5b
with concentration of cyclosporine, prednisone and aza-
thioprine14,15. In study by Malyszko et al. TRAP5b in kid-
ney transplant recipients was within normal range, but
their allograft recipients were enrolled in study 1–10
years after transplantation15. Opposite to their findings
TRAP5b in our study is decreased to normal range in
first six months, afterwards TRAP5b value increases two
times above normal range.
In conclusion it is obvious that patients after renal
transplantation, in spite of normalizing PTH values, still
have increased osteoblast and osteoclast activity. Ob-
serving that, we could say that PTH alone is not the only
factor responsible for bone metabolism disturbances. Se-
veral studies noticed that immunosuppressive therapy,
next to PTH, plays a key role in bone loss after trans-
plantation and that glucocorticoid therapy promotes
osteoclast and inhibits osteoblast activity, leading to de-
velopment of glucocorticoid induced osteoporosis16–18. The
course of bone remodeling after renal transplantation is
guided multifactorially, so furthermore investigations are
needed to establish what factors and how, along with
PTH, contribute to osteoblasts and osteoclasts activity.
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Fig. 3.TRAP5b median and minimal-maximal range in exam-
ined groups; control group, Tx0 = at the time of transplantation,
Tx6 = six months after transplantation, Tx12 = twelve months
after transplantation, * statistically significant versus control.
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POVI[ENI MARKERI KO[TANE PREGRADNJE NAKON TRANSPLANTACIJE BUBREGA
S A @ E T A K
Ko{tana pregradnja je proces koji se neprekidno odvija u naizgled inaktivnom tkivu kao {to je kost. Zbog smanjene
sinteze vitamina D, retencije fosfora i smanjenja koncentracije kalcija u krvi, bolesnici sa kroni~nim bubre`nim zata-
jenjem razvijaju sekundarni hiperparatireoidizam1–5. Povi{ene vrijednosti PTH pomi~u granicu aktivnosti osteoblasta i
osteoklasta na stranu aktivnosti osteoklasta i time ko{tane resorpcije. Ko{tani metaboli~ki poreme}aj koji zahva}a
bolesnike sa kroni~nim bubre`nim zatajenjem nazivamo renalna osteodistrofija1–5. Na{a je pretpostavka da transplan-
tacija bubrega popravlja poreme}aj ko{tanog metabolizma, a cilj je ovog rada vidjeti da li }e se aktivnost osteoblasta i
osteoklasta vratiti na razine prisutne u zdravih pojedinaca.
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